Trial · NCT00488631
Participant flow60
How many started, completed or left each group, period by period.
1 to 20 of 60
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind Period (Week 0-54) | STARTED | Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance | 156 | |
| Double Blind Period (Week 0-54) | STARTED | GLM-I-Rsp-Golimumab 50 mg Maintenance | 154 | |
| Double Blind Period (Week 0-54) | STARTED | GLM-I-Rsp-Golimumab 100 mg Maintenance | 154 | |
| Double Blind Period (Week 0-54) | STARTED | Placebo Induction Responders (PBO-I-Rsp)-Placebo Maintenance | 129 | |
| Double Blind Period (Week 0-54) | STARTED | PBO-I-nonRsp-Golimumab 100 mg Maintenance | 230 | |
| Double Blind Period (Week 0-54) | STARTED | GLM-I-nonRsp-Golimumab 100 mg Maintenance | 405 | |
| Double Blind Period (Week 0-54) | STARTED | Placebo Extension | 0 | |
| Double Blind Period (Week 0-54) | STARTED | Golimumab 50 mg - Extension | 0 | |
| Double Blind Period (Week 0-54) | STARTED | Golimumab 100 mg Extension | 0 | |
| Double Blind Period (Week 0-54) | STARTED | Golimumab 200 mg Extension | 0 | |
| Double Blind Period (Week 0-54) | COMPLETED | Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance | 113 | |
| Double Blind Period (Week 0-54) | COMPLETED | GLM-I-Rsp-Golimumab 50 mg Maintenance | 111 | |
| Double Blind Period (Week 0-54) | COMPLETED | GLM-I-Rsp-Golimumab 100 mg Maintenance | 109 | |
| Double Blind Period (Week 0-54) | COMPLETED | Placebo Induction Responders (PBO-I-Rsp)-Placebo Maintenance | 88 | |
| Double Blind Period (Week 0-54) | COMPLETED | PBO-I-nonRsp-Golimumab 100 mg Maintenance | 127 | |
| Double Blind Period (Week 0-54) | COMPLETED | GLM-I-nonRsp-Golimumab 100 mg Maintenance | 189 | |
| Double Blind Period (Week 0-54) | COMPLETED | Placebo Extension | 0 | |
| Double Blind Period (Week 0-54) | COMPLETED | Golimumab 50 mg - Extension | 0 | |
| Double Blind Period (Week 0-54) | COMPLETED | Golimumab 100 mg Extension | 0 | |
| Double Blind Period (Week 0-54) | COMPLETED | Golimumab 200 mg Extension | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00488631/flow